Trisha Suppes
Professor of Psychiatry and Behavioral Sciences at Stanford University School of Medicine
Data updated
Research Footprint
Trisha Suppes appears in 8 tracked papers (2023–2026), most studied alongside Psilocybin, Placebo and Ketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and PTSD.
Most-cited paper: Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes (91 citations).
Frequent co-authors: Scott Tyler Aaronson, Boris Heifets and Xue Zhang.
Background & Research
Trisha Suppes, MD, PhD, is a psychiatrist and academic researcher at Stanford University School of Medicine. Her work has focused on bipolar disorder, major depression, and rapid-acting or exploratory therapeutics, including psychedelic and empathogen medicine. She is also associated with the VA Palo Alto Health Care System’s bipolar and depression research programs.
Key Impact
She is a leading mood-disorders researcher whose Stanford and VA work includes pioneering clinical studies of psilocybin, ketamine, and other rapid-acting therapies in depression and bipolar disorder.
Collaboration Network
6 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Trisha Suppes is associated with.
Stanford University
academicAt the Stanford School of Medicine, researchers from the Rodriguez Lab and the Heifets Lab have united under the banner of the Stanford Psychedelic Science Group. Their primary clinical focus is to investigate compounds including ketamine, psilocybin, and MDMA as potential treatments for debilitating disorders such as obsessive-compulsive disorder (OCD), treatment-resistant depression, and post-traumatic stress disorder (PTSD).
View stakeholder →National Network of Depression Centers
Non-ProfitThe National Network of Depression Centers is a U.S.-based nonprofit consortium of academic medical centers and mental health programs focused on depression, bipolar disorder, and related mood disorders. It operates nationally across member sites in the United States and is centered in Ann Arbor, Michigan. Its core activities include collaborative research, clinical education, outreach, and network-based improvement of evidence-based care. In the psychedelic-adjacent space, NNDC appears primarily as a mood-disorders research and clinical collaboration network rather than a dedicated psychedelic policy group. Its ketamine task group was created to share information and experience as ketamine and esketamine clinics expanded across the network, and NNDC has also reported on the BIO-K biomarker study of ketamine for major depression. This makes it relevant to researchers, clinicians, and funders working on interventional psychiatry, treatment-resistant depression, and evidence-building around regulated access pathways.
View stakeholder →